Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Pharmacogenetics of tacrolimus: from bench to bedside?].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - 1 Jan 2014

Tavira Beatriz, Díaz-Corte Carmen, Coronel Diego, Ortega Francisco, Coto Eliecer

Abstract excerpt

Tacrolimus (FK-506) is an immunosuppressant widely used to prevent kidney transplant rejection. Patients receive an initial standard dose and tacrolimus levels are measured in blood. If necessary, the dose is adjusted to reach a blood concentration within the accepted range. There is great interindividual variability in the dose required to achieve the target blood level, and many patients require multiple...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Genotype
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney Transplantation

Share to Tacrolimus

Share to Translational Research, Biomedical

Source

Identifiers

PMID: 24463861
DOI: 10.3265/Nefrologia.pre2013.Nov.12267

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Pharmacogenetics of tacrolimus: from bench to bedside?].PMID 24463861Read ↗

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?Semantic proximity Read ↗

Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.Semantic proximity Read ↗

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Semantic proximity Read ↗

Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype.Semantic proximity Read ↗

Genotype-guided tacrolimus dosing: The role of CYP3A5 polymorphisms in optimising kidney transplant immunosuppression in BhutanSemantic proximity Read ↗

Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.Semantic proximity Read ↗

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Semantic proximity Read ↗

[Personalized medicine in transplantation therapy].Semantic proximity Read ↗

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.Semantic proximity Read ↗

A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.Semantic proximity Read ↗

Personalized immunosuppression after kidney transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.